GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GeneNews Limited has announced that it is presenting results of a health economic analysis of the ColonSentry™ test as a screening tool for colorectal cancer. The results are being presented at the Canadian Agency for Drugs and Technologies in Health Symposium in Ottawa, Ontario from April 5-7, 2009.
The abstract entitled, "The Cost-Effectiveness of a Blood Test for Colorectal Cancer Screening" demonstrated that the ColonSentry test detected more early-stage colorectal cancers, saved lives, and lowered the costs associated with late-stage colorectal cancer compared to the fecal occult blood test (FOBT) or no screening.
The results of the decision-analytic model were presented in terms of quality-adjusted life-years (QALY), a standard measure which takes into account both the quantity and quality of life lived. According to GeneNews Limited, from the healthcare perspective, the ColonSentry test was cost-effective versus no screening ($41,227/QALY) and FOBT ($47,699/QALY). For private payers, ColonSentry saved more lives and cost less than FOBT (-$40,124/QALY) or no screening (-$34,726/QALY).
The results of this analysis will also be presented at the Canadian Association for Population Therapeutics Annual Conference held from April 19 - 21, 2009 in Montreal, Quebec. Following this conference, the abstract will be published in The Canadian Journal of Clinical Pharmacology.
The abstract entitled, "The Cost-Effectiveness of a Blood Test for Colorectal Cancer Screening" demonstrated that the ColonSentry test detected more early-stage colorectal cancers, saved lives, and lowered the costs associated with late-stage colorectal cancer compared to the fecal occult blood test (FOBT) or no screening.
The results of the decision-analytic model were presented in terms of quality-adjusted life-years (QALY), a standard measure which takes into account both the quantity and quality of life lived. According to GeneNews Limited, from the healthcare perspective, the ColonSentry test was cost-effective versus no screening ($41,227/QALY) and FOBT ($47,699/QALY). For private payers, ColonSentry saved more lives and cost less than FOBT (-$40,124/QALY) or no screening (-$34,726/QALY).
The results of this analysis will also be presented at the Canadian Association for Population Therapeutics Annual Conference held from April 19 - 21, 2009 in Montreal, Quebec. Following this conference, the abstract will be published in The Canadian Journal of Clinical Pharmacology.